Selective phosphodiesterase type 5 inhibition using tadalafil for the treatment of erectile dysfunction

ISSN： 1354-3784

Source： Expert Opinion on Investigational Drugs, Vol.11, Iss.11, 2002-11, pp. : 1605-1613

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Chronic PDE-5 inhibition in patients with erectile dysfunction – a treatment approach using tadalafil once-daily

By Porst Hartmut Hell-Momeni Katja Büttner Hartwig

Expert Opinion on Pharmacotherapy, Vol. 13, Iss. 10, 2012-07 ,pp. : 1481-1494

Informa Healthcare

Access to resources Recommend Favorite

Phosphodiesterase type 5 (PDE5) inhibitors for the treatment of erectile dysfunction

By Dorsey Philip Keel Christopher Klavens Meghan Hellstrom Wayne JG

Expert Opinion on Pharmacotherapy, Vol. 11, Iss. 7, 2010-05 ,pp. : 1109-1122

Informa Healthcare

Access to resources Recommend Favorite

Vardenafil: a novel type 5 phosphodiesterase inhibitor for the treatment of erectile dysfunction

By Kendirci Muammer Bivalacqua Trinity J Hellstrom Wayne JG

Expert Opinion on Pharmacotherapy, Vol. 5, Iss. 4, 2004-04 ,pp. : 923-932

Informa Healthcare

Access to resources Recommend Favorite

An update on pharmacological treatment of erectile dysfunction with phosphodiesterase type 5 inhibitors

By Bruzziches Roberto

Expert Opinion on Pharmacotherapy, Vol. 14, Iss. 10, 2013-07 ,pp. : 1333-1344

Informa Healthcare

Access to resources Recommend Favorite

Phosphodiesterase Type 5 Inhibitors for the Management of Erectile Dysfunction: Preference and Adherence to Treatment

Current Pharmaceutical Design, Vol. 15, Iss. 30, 2009-10 ,pp. : 3486-3495

Bentham Science Publishers

Access to resources Recommend Favorite